- Home
- QDEL
as of 03-04-2026 3:30pm EST
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.6B | IPO Year: | 2022 |
| Target Price: | $32.75 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -16.69 | EPS Growth: | 45.35 |
| 52 Week Low/High: | $19.50 - $41.40 | Next Earning Date: | N/A |
| Revenue: | $2,730,200,000 | Revenue Growth: | -1.89% |
| Revenue Growth (this year): | 3.51% | Revenue Growth (next year): | 3.86% |
| P/E Ratio: | -1.29 | Index: | N/A |
| Free Cash Flow: | -83000000.0 | FCF Growth: | N/A |
AI-Powered QDEL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of QuidelOrtho Corporation (QDEL)
Chief Financial Officer
Avg Cost/Share
$23.66
Shares
3,370
Total Value
$79,741.95
Owned After
10,290
SEC Form 4
Director
Avg Cost/Share
$23.96
Shares
10,000
Total Value
$239,586.00
Owned After
27,775
SEC Form 4
President and CEO
Avg Cost/Share
$23.59
Shares
10,540
Total Value
$248,660.73
Owned After
40,073
SEC Form 4
Director
Avg Cost/Share
$28.28
Shares
750
Total Value
$21,206.25
Owned After
15,021
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Busky Joseph M | QDEL | Chief Financial Officer | Feb 13, 2026 | Buy | $23.66 | 3,370 | $79,741.95 | 10,290 | |
| Strobeck Matthew | QDEL | Director | Feb 13, 2026 | Buy | $23.96 | 10,000 | $239,586.00 | 27,775 | |
| Blaser Brian J | QDEL | President and CEO | Feb 13, 2026 | Buy | $23.59 | 10,540 | $248,660.73 | 40,073 | |
| RHOADS ANN D | QDEL | Director | Dec 10, 2025 | Buy | $28.28 | 750 | $21,206.25 | 15,021 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 11, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 11, 2026 · 100% conf.
1D
+8.94%
$31.37
5D
+6.40%
$30.64
20D
+3.09%
$29.69
qdel-202602110001906324false00019063242026-02-112026-02-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 11, 2026
QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)
Delaware 001-41409
87-4496285
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
9975 Summers Ridge Road, San Diego, California 92121 (Address of principal executive offices, including zip code) (858) 552-1100 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 11, 2026, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its fourth quarter and full year ended December 28, 2025 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on February 11, 2026 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished with this Form 8-K:
Exhibit NumberDescription of Exhibit 99.1Press release, dated February 11, 2026, reporting QuidelOrtho Corporation's financial results for its fourth quarter and full year ended December 28, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 11, 2026
QUIDELORTHO CORPORATION
By:/s/ Joseph M. Busky Name:Joseph M. Busky Its:Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
Q3 2025 Earnings
8-KNov 5, 2025
qdel-202511050001906324false00019063242025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 5, 2025
QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)
Delaware 001-41409
87-4496285
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
9975 Summers Ridge Road, San Diego, California 92121 (Address of principal executive offices, including zip code) (858) 552-1100 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2025, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its third quarter ended September 28, 2025 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 5, 2025 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished with this Form 8-K:
Exhibit NumberDescription of Exhibit 99.1Press release, dated November 5, 2025, reporting QuidelOrtho Corporation's financial results for its third quarter ended September 28, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2025
QUIDELORTHO CORPORATION
By:/s/ Joseph M. Busky Name:Joseph M. Busky Its:Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
Q2 2025 Earnings
8-KAug 5, 2025
qdel-202508050001906324false00019063242025-08-052025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 5, 2025
QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)
Delaware 001-41409
87-4496285
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
9975 Summers Ridge Road, San Diego, California 92121 (Address of principal executive offices, including zip code) (858) 552-1100 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its second quarter ended June 29, 2025 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on August 5, 2025 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished with this Form 8-K:
Exhibit NumberDescription of Exhibit 99.1Press release, dated August 5, 2025, reporting QuidelOrtho Corporation's financial results for its second quarter ended June 29, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 5, 2025
QUIDELORTHO CORPORATION
By:/s/ Joseph M. Busky Name:Joseph M. Busky Its:Chief Financial Officer
Compare QDEL vs Leading Stocks
See how QDEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "QDEL QuidelOrtho Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.